Phase i trials of targeted anticancer drugs: A need to refocus

Nature Reviews Drug Discovery

Volumn 11, Issue 12, 2012, Pages 889-890

  Borden, Ernest C ^a   Dowlati, Afshin ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANOREXIA; BIOPSY; BLOOD ANALYSIS; CANCER RESEARCH; CIRCULATING TUMOR CELL; DEHYDRATION; DIARRHEA; DRUG FATALITY; DRUG SAFETY; FATIGUE; HUMAN; MAXIMUM TOLERATED DOSE; MOLECULARLY TARGETED THERAPY; NAUSEA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STOMATITIS; STUDY DESIGN; THROMBOCYTOPENIA; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; NEOPLASMS; RESEARCH DESIGN;

EID: 84870790055     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3909     Document Type: Review

References (5)

1. American Society of Clinical Oncology. 2012 ASCO Annual Meeting Proceedings [online], http://www.asco.org/ASCOv2/Attendee%20Resource%20Center/ 2012%20Annual%20Meeting/Rev-AM%20Proceedings%20I%202012%20cover%20to%20cover%20 print%20FINAL.pdf (2012).
2. Glassman, R. H. & Ratain, M. J. Biomarkers in early cancer drug development: limited utility. Clin. Pharmacol. Ther. 85, 134-135 (2009).
3. Kummar, S. et al. Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur. J. Cancer 45, 741-746 (2009).
4. Goodwin, R. et al. Targeted agents: how to select winners in preclinical and early clinical studies? Eur. J. Cancer 48, 170-178 (2012).
5. Le Tourneau, C., Lee, J. J. & Siu, L. L. Dose escalation methods in Phase I cancer clinical trials. J. Natl Cancer Inst. 101, 708-720 (2009).